FDA approval paves the way for AcouSort’s first OEM commercialization within critical care diagnostics


AcouSort AB (publ) (“AcouSort”, the “Company”) today announces that the Company and its partner within critical care diagnostics have updated their collaboration agreement. The updated agreement follows the FDA approval in the fall of 2023 for the partnering company’s next generation point-of-care diagnostic system containing AcouSort’s acoustofluidics technology. Minimum revenues from the partnership in 2024 are expected to reach approximately SEK 3.5M. 

AcouSort and its partner within critical care diagnostics have updated their collaboration agreement, and the commercial phase of the collaboration will start at the beginning of 2024. Both minimum and per product royalties have been index adjusted going forward and AcouSort’s minimum revenues from the partnership in 2024 is expected to be around SEK 3.5 million. 

The collaboration with this partnering company is the first full-blown success for our research-to-OEM strategy and serves as proof-of-concept of our business model. The commercialization of our partnering company’s new system with integrated acoustofluidics technology is one of the most significant milestones in the history of AcouSort and we could not be happier. The FDA approval is a validation of our technology that greatly strengthens our market position across all discussions with potential diagnostic and life science partners,” says Torsten Freltoft, AcouSort’s CEO.

This information is information that AcouSort AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person below, for publication on December 11, 2023, at 10.00 pm.


Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com 


AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company’s products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company’s products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – socalled Point-of Care (POC) systems. The company’s commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company’s research instruments. With the help of the company’s products and development of point-ofcare tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The Company’s Certified Adviser is Carnegie Investment Bank AB (publ).